New drug trial offers hope for Hard-to-Treat bowel disease

NCT ID NCT06127043

Ongoing Disease control Sponsor: AnaptysBio, Inc. Source: ClinicalTrials.gov ↗

Summary

This study is testing an investigational drug called rosnilimab for people with moderate to severe ulcerative colitis (UC) who haven't gotten enough relief from other standard treatments. About 132 participants will be randomly assigned to receive either the drug or a placebo (inactive substance) for 12 weeks. The main goal is to see if rosnilimab safely reduces bowel inflammation and symptoms better than the placebo.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

AnaptysBio Investigational Site 10-103

Kingsport, Tennessee, 37663, United States
AnaptysBio Investigational Site 10-104

Dallas, Texas, 75246, United States
AnaptysBio Investigational Site 10-106

Miami, Florida, 33165, United States
AnaptysBio Investigational Site 10-107

Seattle, Washington, 98195, United States
AnaptysBio Investigational Site 10-108

San Jose, California, 95124, United States
AnaptysBio Investigational Site 10-109

Miami Gardens, Florida, 33014, United States
AnaptysBio Investigational Site 10-112

Lancaster, California, 93534, United States
AnaptysBio Investigational Site 10-113

Garland, Texas, 75044, United States
AnaptysBio Investigational Site 10-115

Phoenix, Arizona, 85018, United States
AnaptysBio Investigational Site 10-117

Garden Grove, California, 92845, United States
AnaptysBio Investigational Site 10-118

Las Vegas, Nevada, 89128, United States
AnaptysBio Investigational Site 10-120

Norman, Oklahoma, 73017, United States
AnaptysBio Investigational Site 10-122

Atlanta, Georgia, 30328, United States
AnaptysBio Investigational Site 10-123

Orlando, Florida, 32822, United States
AnaptysBio Investigational Site 10-124

Oak Lawn, Illinois, 60453, United States
AnaptysBio Investigational Site 10-125

Tampa, Florida, 33607, United States
AnaptysBio Investigational Site 10-127

Brooksville, Florida, 34601, United States
AnaptysBio Investigational Site 10-129

Lancaster, California, 93534, United States
AnaptysBio Investigational Site 10-130

Southlake, Texas, 76092, United States
AnaptysBio Investigational Site 10-131

Orlando, Florida, 32789, United States
AnaptysBio Investigational Site 10-132

Tyler, Texas, 75701, United States
AnaptysBio Investigational Site 10-133

Utica, New York, 13501, United States
AnaptysBio Investigational Site 10-134

Lubbock, Texas, 79382, United States
AnaptysBio Investigational Site 10-135

Georgetown, Texas, 78626, United States
AnaptysBio Investigational Site 10-136

Cincinnati, Ohio, 45201, United States
AnaptysBio Investigational Site 11-102

London, Ontario, Canada
AnaptysBio Investigational Site 11-103

Montreal, Quebec, Canada
AnaptysBio Investigational Site 11-105

Calgary, Canada
AnaptysBio Investigational Site 12-101

Innsbruck, Austria
AnaptysBio Investigational Site 12-102

Vienna, Austria
AnaptysBio Investigational Site 12-103

Sankt Pölten, Austria
AnaptysBio Investigational Site 12-104

Salzburg, Austria
AnaptysBio Investigational Site 16-101

Tours, France
AnaptysBio Investigational Site 16-102

Nantes, France
AnaptysBio Investigational Site 16-103

Nantes, France
AnaptysBio Investigational Site 17-101

Duisburg, Germany
AnaptysBio Investigational Site 17-103

Kiel, Germany
AnaptysBio Investigational Site 17-105

Dachau, Germany
AnaptysBio Investigational Site 17-106

Brandenburg, Germany
AnaptysBio Investigational Site 17-107

Berlin, Germany
AnaptysBio Investigational Site 17-108

Hamburg, Germany
AnaptysBio Investigational Site 17-109

Ulm, Germany
AnaptysBio Investigational Site 17-110

Erlangen, Germany
AnaptysBio Investigational Site 20-102

Rozzano, Italy
AnaptysBio Investigational Site 20-104

San Giovanni, Italy
AnaptysBio Investigational Site 20-105

Milan, Italy
AnaptysBio Investigational Site 20-106

Udine, Italy
AnaptysBio Investigational Site 20-107

Pavia, Italy
AnaptysBio Investigational Site 20-108

Legnano, Italy
AnaptysBio Investigational Site 20-109

San Donato, Italy
AnaptysBio Investigational Site 20-110

Catania, Italy
AnaptysBio Investigational Site 20-111

Cagliari, Italy
AnaptysBio Investigational Site 20-112

Bologna, Italy
AnaptysBio Investigational Site 20-113

Turin, Italy
AnaptysBio Investigational Site 21-101

Amsterdam, Netherlands
AnaptysBio Investigational Site 24-102

Alicante, Spain
AnaptysBio Investigational Site 24-103

Lleida, Spain
AnaptysBio Investigational Site 27-101

London, United Kingdom
AnaptysBio Investigational Site 27-102

Cambridge, United Kingdom
AnaptysBio Investigational Site 27-103

Belfast, United Kingdom
AnaptysBio Investigational Site 27-104

York, United Kingdom
AnaptysBio Investigational Site 27-105

Runcorn, United Kingdom
AnaptysBio Investigational Site 27-106

Liverpool, United Kingdom
AnaptysBio Investigational Site 27-107

Shrewsbury, United Kingdom
AnaptysBio Investigational Site 30-101

Warsaw, Poland
AnaptysBio Investigational Site 30-101

Bucharest, Romania
AnaptysBio Investigational Site 30-102

Katowice, Poland
AnaptysBio Investigational Site 30-103

Lodz, Poland
AnaptysBio Investigational Site 30-104

Poznan, Poland
AnaptysBio Investigational Site 30-106

Częstochowa, Poland
AnaptysBio Investigational Site 30-107

Warsaw, Poland
AnaptysBio Investigational Site 30-108

Bydgoszcz, Poland
AnaptysBio Investigational Site 30-109

Warsaw, Poland
AnaptysBio Investigational Site 30-110

Torun, Poland
AnaptysBio Investigational Site 30-111

Krakow, Poland
AnaptysBio Investigational Site 30-112

Elblag, Poland
AnaptysBio Investigational Site 30-113

Sopot, Poland
AnaptysBio Investigational Site 30-114

Lublin, Poland
AnaptysBio Investigational Site 30-115

Katowice, Poland
AnaptysBio Investigational Site 30-116

Rzeszów, Poland
AnaptysBio Investigational Site 30-117

Poznan, Poland
AnaptysBio Investigational Site 30-119

Lodz, Poland
AnaptysBio Investigational Site 30-120

Poznan, Poland
AnaptysBio Investigational Site 30-123

Krakow, Poland
AnaptysBio Investigational Site 31-102

Timișoara, Romania
AnaptysBio Investigational Site 31-103

Cluj-Napoca, Romania
AnaptysBio Investigational Site 58-101

Belgrade, Serbia
AnaptysBio Investigational Site 58-102

Zrenjanin, Serbia
AnaptysBio Investigational Site 58-103

Belgrade, Serbia
AnaptysBio Investigational Site 58-104

Belgrade, Serbia
AnaptysBio Investigational Site 58-105

Belgrade, Serbia
AnaptysBio Investigational Site 59-101

Tbilisi, Georgia, 0160, Georgia
AnaptysBio Investigational Site 59-102

Tbilisi, 0141, Georgia
AnaptysBio Investigational Site 59-103

Tbilisi, 0102, Georgia
AnaptysBio Investigational Site 59-104

Tbilisi, 0160, Georgia
AnaptysBio Investigational Site 59-105

Tbilisi, 0180, Georgia
AnaptysBio Investigational Site 59-106

Tbilisi, 0101, Georgia
AnaptysBio Investigational Site 61-102

Sofia, Bulgaria
AnaptysBio Investigational Site 74-101

Zagreb, Croatia
AnaptysBio Investigational Site 74-104

Rijeka, Croatia

Conditions

Explore the condition pages connected to this study.

ULCERATIVE COLITIS